Loading...
•
Sep 30, 2025
CRISPR Therapeutics Q3 2025 Earnings Report
CRISPR Therapeutics reported a net loss in Q3 2025 as R&D and collaboration expenses remained high despite a modest increase in grant revenue.
Key Takeaways
CRISPR Therapeutics posted a net loss of $106.4 million in Q3 2025 on revenue of $889,000. While R&D costs declined year-over-year, collaboration expenses rose significantly. The company maintains a strong cash position of $1.9 billion and continues advancing multiple clinical programs.
Revenue reached $889,000 in Q3 2025, solely from grant income.
Net loss widened to $106.4 million compared to $85.9 million in Q3 2024.
Cash, cash equivalents, and marketable securities totaled $1.94 billion at quarter end.
R&D expenses decreased to $58.9 million, while collaboration expenses surged to $57.1 million.
Revenue by Segment
Forward Guidance
The company projects continued momentum across its clinical pipeline, with CASGEVY revenue expected to exceed $100 million in 2025 and significant growth forecasted for 2026.
Positive Outlook
- Strong CASGEVY adoption with 39 patients infused to date.
- Enrollment completed in global pediatric Phase 3 studies for exa-cel.
- Positive Phase 1 data for CTX310 presented and published.
- First patient dosed in Phase 2 trial of SRSD107.
- Robust cash position supports long-term pipeline development.
Challenges Ahead
- Continued net losses despite clinical progress.
- High collaboration expenses impacting profitability.
- Minimal revenue outside of grants in Q3 2025.
- R&D costs, while reduced, remain a substantial burden.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...